Biotech | October 07, 2021
Moderna to build mRNA facility in Africa
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
Now all districts of the country will have commissioned PSA Oxygen plants
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT
Subscribe To Our Newsletter & Stay Updated
